| 生物活性 |
DA-1241 is an orally active GPR119 agonist and NF-κB inhibitor with EC50 values of 4.37 nM, 71.5 nM, 156 nM, and 14.7 nM for human, mouse, rat, and hamster GPR119, respectively, and an IC50 of 84.2 nM for NF-κB; it exerts glucose-lowering effects by activating GPR119 to stimulate intestinal GLP-1 secretion, induce autophagy-mediated degradation of lipid droplets, and inhibit hepatic gluconeogenesis, protects liver function by inhibiting activation of the NF-κB pathway to reduce macrophage differentiation and the release of pro-inflammatory cytokines and to suppress apoptosis (apoptosis), and protects β-cell function by inhibiting ER stress and maintaining PDX1 expression, and can be used for research on metabolic dysfunction-associated steatohepatitis, type 2 diabetes, and non-alcoholic fatty liver disease. |
体外研究 (In Vitro) |
DA-1241 (10 μM;4 h) 可抑制 TNFα 诱导的人肝癌细胞 HepG2 中 NFκB p65 的核转位。 DA-1241 (10 μM;48 h) 可减弱 LPS (MS-X54539) 诱导的 NF-κB 通路激活、炎症小体组分上调,以及人 THP-1 巨噬细胞中促炎细胞因子 (IL-1β、TNFα) 的分泌。 DA-1241 (1000 nM; 24 h) 可降低饥饿状态下 HepG2 细胞中糖异生酶 G6Pase 和 PEPCK 的表达。 DA-1241 (1000 nM; 24 h) 可调控自噬流标志物,在饥饿的 HepG2 细胞中促进 LC3-I 向 LC3-II 的转化并上调 p62 蛋白表达。 DA-1241 (1000 nM; 24 h) 可降低经饥饿处理、转染 mRFP-GFP-LC3 的 HepG2 细胞中的自噬流,表现为黄色 LC3 斑点增加、红色 LC3 斑点减少。 DA-1241 (100 μM; 18 h) 以依赖 GPR119 的方式在 Hep3B 细胞和 GFP-TFEB HeLa 细胞中诱导自噬、TFEB 核转位、cAMP 升高并减少脂质积累,而 GPR119 敲低可消除这些作用。 DA-1241 (0.01 nM-10 μM;1 h) 可强效提升 HIT-T15 仓鼠胰岛素瘤细胞内的 cAMP 水平,其 EC50 为 14.7 nM。 DA-1241 (0.01-100 μM;30 min) 可强效刺激 HIT-T15 仓鼠胰岛素瘤细胞中葡萄糖依赖性的胰岛素分泌,其 EC50 为 22.3 nM。 DA-1241 (0.1-1 μM;8 h) 可显著抑制毒胡萝卜素诱导的 HIT-T15 仓鼠胰岛素瘤细胞凋亡,使凋亡率降至接近对照组水平。 DA-1241 (0.1-10 μM) 可浓度依赖性地抑制毒胡萝卜素诱导的 HIT-T15 仓鼠胰岛素瘤细胞中内质网应激标记基因 BiP 和 CHOP 的表达,在 10 μM 浓度下抑制作用显著。 DA-1241 (1-10 μM; 6 h) 可抑制毒胡萝卜素诱导的 JNK、ERK1/2 和 p38 MAPK 活化,并降低 HIT-T15 仓鼠胰岛素瘤细胞中内质网应激标志物 BiP 和 CHOP 的蛋白表达。 DA-1241 (0.1 μM;6 h) 对毒胡萝卜素诱导的 HIT-T15 仓鼠胰岛素瘤细胞内质网应激具有保护作用,该作用依赖于 GPR119 的激活,因为敲低 GPR119 可消除 DA-1241 的活力挽救效应。
Immunofluorescence
| Cell Line: |
human HepG2 hepatoma cells |
| Concentration: |
10 μM |
| Incubation Time: |
4 h (pre-incubation); 0.5 h (TNFα stimulation) |
| Result: |
Prevented TNFα-induced nuclear translocation of the NFκB p65 subunit, retaining p65 in the cytosol instead of allowing it to accumulate in the nucleus. |
ELISA Assay
| Cell Line: |
parental and GPR119 KO human THP-1 macrophages |
| Concentration: |
0, 0.3, 1, 3, 10 μM |
| Incubation Time: |
48 h (PMA-induced differentiation); 4 h (LPS stimulation) |
| Result: |
Inhibited LPS-induced TNFα secretion in a concentration-dependent manner in parental THP-1 macrophages. Had no effect on LPS-induced TNFα secretion in GPR119 KO THP-1 macrophages at any tested concentration. |
Western Blot Analysis
| Cell Line: |
human hepatocellular carcinoma HepG2 cells |
| Concentration: |
1000 nM |
| Incubation Time: |
24 h (with bafilomycin A1 added for final 2 h) |
| Result: |
Increased LC3-I to LC3-II conversion, an effect augmented by bafilomycin A1 co-treatment, and increased protein expression of p62. |
Immunofluorescence
| Cell Line: |
human hepatocellular carcinoma HepG2 cells (mRFP-GFP-LC3-transfected) |
| Concentration: |
1000 nM |
| Incubation Time: |
24 h (with bafilomycin A1 added for final 2 h) |
| Result: |
Increased the number of yellow LC3-GFP puncta and decreased the number of red mRFP puncta, and reduced the mRFP/GFP-LC3 ratio, indicating reduced autophagic flux. |
Cell Viability Assay
| Cell Line: |
HIT-T15 hamster insulinoma cells |
| Concentration: |
0.001-10 μM (co-treated with 0.3 μM thapsigargin) |
| Incubation Time: |
8 h |
| Result: |
Restored cell viability reduced by thapsigargin-induced ER stress in a concentration-dependent manner. Significantly increased viability at all tested concentrations. |
Apoptosis Analysis
| Cell Line: |
HIT-T15 hamster insulinoma cells |
| Concentration: |
0.1 μM, 1 μM (co-treated with 0.3 μM thapsigargin) |
| Incubation Time: |
8 h |
| Result: |
Reduced the apoptosis rate from 51.65% (thapsigargin alone) to 13.37% at 0.1 μM. Reduced the apoptosis rate from 51.65% (thapsigargin alone) to 12.75% at 1 μM. |
Western Blot Analysis
| Cell Line: |
HIT-T15 hamster insulinoma cells |
| Concentration: |
1 μM, 10 μM (co-treated with 1 μM thapsigargin) |
| Incubation Time: |
6 h |
| Result: |
Attenuated thapsigargin-induced phosphorylation of JNK, ERK1/2, and p38 MAPK in a concentration-dependent manner. Reduced phosphorylated JNK to 1.15 folds of control at 10 μM. Reduced phosphorylated ERK1/2 to 1.19 folds of control at 10 μM. Reduced phosphorylated p38 MAPK to 1.61 folds of control at 10 μM. Reduced BiP protein to 0.769 folds of control at 10 μM. Reduced CHOP protein to 0.789 folds of control at 10 μM. |
Cell Viability Assay
| Cell Line: |
siRNA-treated HIT-T15 hamster insulinoma cells |
| Concentration: |
0.1 μM (co-treated with 1 μM thapsigargin, 48 h after siGPR119 transfection) |
| Incubation Time: |
6 h |
| Result: |
Failed to significantly preserve viability in siGPR119-transfected cells. Significantly rescued viability in control siRNA-transfected cells.
|
|
体内研究 (In Vivo) |
DA-1241 (10-100 mg/kg; p.o.; 每日给药;连续 4 周) 可呈剂量依赖性地改善 MS-MASH 小鼠的血糖控制,并降低 MASH 相关的肝脏脂肪变性、炎症反应及甘油三酯水平,其降血糖功效在 30 mg/kg 时进入平台期。 DA-1241 (30-100 mg/kg/天;灌胃;每日;通过药物-饲料混合给药 8-12 周) 可减轻 DIO-MASH 小鼠中与 MASH 相关的肝脂肪变性、炎症、纤维化及肝损伤。 DA-1241 (1-10 mg/kg;灌胃;单次给药) 可剂量依赖性地抑制正常 ICR 小鼠餐后血浆甘油三酯的升高。 DA-1241 (120 mg/kg;每日给药;持续 12 周) 可通过促进 GLP-1 分泌以增强葡萄糖依赖性胰岛素释放,并抑制肝脏糖异生,改善高脂饮食诱导的糖尿病小鼠的血糖控制。 DA-1241 (100 mg/kg 每日给药,持续 4 周) 可通过 TFEB 介导的自噬诱导作用减轻 C57BL/6J 小鼠中由高脂饮食 (HFD) 诱导的非酒精性脂肪性肝病 (NAFLD),降低肝脏 TG 水平与 NAFLD 活动评分,并改善葡萄糖及胰岛素耐受性。 DA-1241 (0.3-30 mg/kg;灌胃;葡萄糖负荷前 30 分钟单次给药) 可剂量依赖性地降低正常 SD 大鼠的餐后血糖波动。 DA-1241 (3 mg/kg;灌胃;葡萄糖负荷前 30 分钟单次给药) 可通过提升血浆胰岛素及总 GLP-1 水平,降低野生型小鼠的餐后血糖波动。 DA-1241 (100 mg/kg/天;灌胃;每日;通过药物-饲料混合给药 10 周) 可改善血糖和甘油三酯控制,通过上调 PDX1 表达维持胰岛 β 细胞量,并在 HFD/STZ 诱导的糖尿病 ICR 小鼠中抑制内质网应激。
| Animal Model: |
MS-MASH (5-week-old male; MASH model via 60% kcal fat high-fat diet) |
| Dosage: |
10 mg/kg; 30 mg/kg; 100 mg/kg |
| Administration: |
p.o.; daily; 4 weeks |
| Result: |
Inhibited fed blood glucose levels by 18.1%, 27.9%, and 27.5% at 10, 30, and 100 mg/kg respectively relative to vehicle control at week 4.\nLowered fasting plasma glucose, glycated hemoglobin, and fasting plasma triglyceride levels with 43.4 ± 3.7% inhibition vs. vehicle control.\nReduced the NAFLD Activity Score at all tested doses, with reduced hepatic steatosis and immune cell infiltration observed via histological analysis. |
| Animal Model: |
Lep^ob/Lep^ob (Ob) (male; MASH model via 10 weeks of Western diet feeding) |
| Dosage: |
30 mg/kg/day; 100 mg/kg/day |
| Administration: |
p.o.; daily; 10 weeks; via drug-diet admixture |
| Result: |
Reduced the NAFLD Activity Score and liver fibrosis score, and increased plasma total GLP-1 levels significantly at 100 mg/kg/day relative to vehicle control.\nShowed trends toward improvement in NAFLD Activity Score, liver fibrosis score, and plasma total GLP-1 levels at 30 mg/kg/day. |
| Animal Model: |
C57BL/6 J STAM (8-week-old male; MASH model via neonatal streptozotocin injection plus high-fat diet feeding) |
| Dosage: |
30 mg/kg |
| Administration: |
p.o.; daily; 4 weeks |
| Result: |
Reduced the NAFLD Activity Score significantly by alleviating steatosis, inflammation, and hepatocyte ballooning relative to vehicle control.\nReduced the hepatic Sirius red-positive fibrotic area fraction by 35.8%, though this did not reach statistical significance. |
| Animal Model: |
C57BL/6 J (male; MASH model via 27 weeks of Western diet feeding, pre-biopsied for fibrosis stage 1 or 2) |
| Dosage: |
30 mg/kg/day; 100 mg/kg/day; 100 mg/kg/day (in combination with 150 mg/kg/day sitagliptin) |
| Administration: |
p.o.; daily; 8 weeks; via drug-diet admixture |
| Result: |
Reduced relative liver weight, hepatic cholesterol content, plasma ALT, AST, ALT/AST ratio, hepatic steatosis area, type I collagen area, and galectin-3-positive immune cell infiltration area at 30 mg/kg/day relative to vehicle control.\n Further reduced relative liver weight, hepatic cholesterol content, plasma ALT/AST ratio, and decreased plasma free fatty acids, TIMP1, and type IV collagen levels at 100 mg/kg/day relative to vehicle control.\n Produced greater improvements in combination with 150 mg/kg/day Sitagliptin (MS-M62474).\n Downregulated 17 hepatic inflammatory signaling genes in DA-1241-treated groups via transcriptome analysis. |
| Animal Model: |
C57BL/6 J (male; MASH model via 30 weeks of Western diet feeding, pre-biopsied for fibrosis stage 1 or 2) |
| Dosage: |
100 mg/kg/day; 100 mg/kg/day (in combination with 200 mg/kg/day evogliptin) |
| Administration: |
p.o.; daily; 12 weeks; via drug-diet admixture |
| Result: |
Reduced plasma ALT, AST, galectin-3-positive immune cell infiltration area, αSMA-positive stellate cell activation area, and plasma PINP, TIMP1, and type IV collagen levels at 100 mg/kg/day relative to vehicle control.\n Produced greater improvements in combination with 200 mg/kg/day Evogliptin (MS-X11879). |
| Animal Model: |
ICR (7-week-old male; non-diseased, used for oral triglyceride tolerance testing) |
| Dosage: |
1 mg/kg; 3 mg/kg; 10 mg/kg; 3 mg/kg (in combination with 30 mg/kg sitagliptin); 10 mg/kg (in combination with 30 mg/kg sitagliptin) |
| Administration: |
p.o.; single dose |
| Result: |
Reduced post-prandial plasma triglyceride levels dose-dependently, with 1.3%, 23.5%, and 31.2% reduction at 1, 3, and 10 mg/kg respectively.\n Reduced the area under the plasma triglyceride curve (AUC0-6h) at 10 mg/kg. Produced a greater reduction in peak plasma triglycerides in combination with 30 mg/kg sitagliptin than either agent alone, and significantly increased plasma total and active GLP-1 levels at 1.5 hours post-lipid challenge relative to vehicle control and monotherapy groups. |
| Animal Model: |
C57BL/6J (5-week-old male; acclimatized from 4 weeks old; high-fat diet-induced hyperglycaemia) |
| Dosage: |
120 mg/kg |
| Administration: |
daily; 12 weeks |
| Result: |
Reduced fasting blood glucose levels significantly.\n Improved oral glucose tolerance significantly.\n Increased serum total GLP-1 levels during oral glucose tolerance test significantly. Increased serum insulin level 30 minutes after oral glucose challenge significantly. Reduced hepatic triglyceride content significantly.\n Reduced serum cholesterol levels significantly.\n Attenuated hepatic protein expression of gluconeogenic enzymes glucose 6-phosphatase and phosphoenolpyruvate carboxykinase. Showed no significant effects on body weight gain, food intake, intraperitoneal glucose tolerance, or insulin tolerance. |
| Animal Model: |
C57BL/6J mice |
| Dosage: |
100 mg/kg per day |
| Administration: |
daily; 4 weeks |
| Result: |
Reduced body weight in HFD-fed mice.\n Reduced area under the curve (AUC) of oral glucose tolerance test (OGTT) results, improving glucose tolerance.\n Reduced AUC of insulin tolerance test (ITT) results, improving insulin sensitivity.\nSignificantly reduced serum AST, ALT, and TG levels.\n Reduced hepatic TG levels.\nReduced hepatic steatosis, lobular inflammation, hepatocellular ballooning, and NAFLD activity scores.\nIncreased the number of autophagic vesicles and lysosomes in liver tissue.\n Elevated liver LC3II protein levels, decreased liver p62 protein levels.\n Enhanced TFEB nuclear translocation in liver tissue. |
| Animal Model: |
Liver-specific Tfeb knockout (L-Tfeb KO) mice (male, 5-6 weeks old); TFEB wild-type (WT) littermate mice (male, 5-6 weeks old) |
| Dosage: |
100 mg/kg per day |
| Administration: |
daily; 4 weeks |
| Result: |
In TFEB WT HFD-fed mice: Reduced body weight.\nReduced OGTT AUC, improving glucose tolerance.\n Reduced ITT AUC, improving insulin sensitivity.\nReduced serum AST, ALT, and TG levels.\nReduced hepatic TG levels.\nReduced hepatic steatosis, lobular inflammation, hepatocellular ballooning, and NAFLD activity scores.\n Increased the number of autophagic vesicles and lysosomes in liver tissue. Elevated liver LC3II protein levels, decreased liver p62 protein levels. |
| Animal Model: |
Sprague-Dawley (SD) (8-week-old male) |
| Dosage: |
0.3, 3, 30 mg/kg |
| Administration: |
p.o.; single dose 30 minutes pre-glucose challenge |
| Result: |
Significantly and dose-dependently lowered blood glucose levels compared to vehicle control.\nReduced incremental glucose AUC (0-120 min) in a dose-dependent manner. |
| Animal Model: |
wild-type C57BL/6 (male); GPR119 knockout (KO) (male) |
| Dosage: |
3 mg/kg |
| Administration: |
p.o.; single dose 30 minutes pre-glucose challenge |
| Result: |
Significantly reduced postprandial blood glucose levels from 30 minutes post-challenge in wild-type mice. Did not significantly increase active GLP-1 levels in wild-type mice. |
| Animal Model: |
ICR (10-week-old male; HFD/STZ-induced diabetic) |
| Dosage: |
100 mg/kg/day |
| Administration: |
p.o.; daily; 10 weeks via drug-diet admixture |
| Result: |
Significantly lowered fed and fasted blood glucose levels compared to diabetic vehicle control.\n Reduced plasma triglyceride levels to 329.4 mg/dl.\n Reduced liver triglyceride contents compared to diabetic vehicle control.\n Significantly restored the PDX1-positive islet area from 32.98% to 53.72%.\n Increased the insulin-positive islet area compared to diabetic vehicle control.\n Suppressed the glucagon-positive islet area from 20.19% to 7.13%.\n Significantly reduced the BiP-positive islet area in diabetic mice compared to diabetic vehicle control. |
|